Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Reports Sharp Decrease in Revenues

NEW YORK (GenomeWeb News) – Canadian blood-based biomarker development company GeneNews today reported a sharp drop in revenues and a 53 percent rise in its net loss for the first quarter of 2008.
The company reported Q1 revenues of CDN$294,286 ($288,827USD), a drop of 82.4 percent from revenues of CDN$1.7 million in the first quarter of 2007.
GeneNews’s first quarter revenue came from an ongoing US$2 million collaboration with an Asian biomedical consortium to test prostate disease biomarkers. Its 2007 Q1 revenue came from a collaboration with Pfizer.
The company posted a net loss of CDN$2.6 million, or CDN$0.05 per share, versus a loss of CDN$1.7 million, or CDN$.03 per share, in last year’s first quarter.
Its total operating expenditures decreased over the same period last year — from CDN$3.5 million in Q1 of 2007 to CDN$2.9 million in Q1 of 2008. Its R&D spending fell to CDN$2.2 million from CDN$2.7 million in Q1 of 2007, while its general and administrative costs were also down slightly at CDN$512,560 compared to CDN$593,819 last year.
The company finished the quarter with cash and cash equivalents of CDN$9.1 million. Based on this figure, GeneNews believes it has sufficient resources to continue into Q2 of 2009.
GeneNews President and CEO K. Wayne Marshall said the company is on track to commercialize a laboratory-based risk stratification test for colorectal cancer by the third quarter of 2008, which will be offered by the GeneNews clinical reference lab north of Toronto, Canada.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.